Inhibitors of PCSK9 have been approved for the treatment of atherosclerotic cardiovascular diseases associated with hypercholesterolemia, however, a central role on immune tolerance in oncology has recently been investigated [99]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.